secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001493152-24-051191
Event type: other
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 shows copper-binding ability; Wilson's disease program advanced
-------------------------------------------------------------------------

- Preclinical studies show Telomir-1 strongly binds copper, targeting Wilson's disease caused by copper accumulation.
- Company plans IND/INAD submission by Q4 2025, with clinical trials expected in 2026.
- Telomir-1 also interacts with essential ions, potentially improving on current Wilson's treatments.
- Telomir is advancing preclinical studies in Wilson's disease while exploring other copper-related conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224051191/0001493152-24-051191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224051191/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-051191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer